Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 7/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21432161 | 0.89 | CACNA1H (0.31) | — | |
| SCHEMBL28361097 | 0.87 | CSNK1D (0.35) | FADS1HTR6HSD11B1ROCK2ROCK1 | |
| SCHEMBL21432176 | 0.86 | BRAF (0.33) | — | |
| SCHEMBL21432162 | 0.84 | NPC1 (0.31) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17926042 | 0.84 | FADS1 (0.36) | FADS1HTR6HSD11B1ROCK2ROCK1 | |
| SCHEMBL21506794 | 0.84 | FADS1 (0.36) | FADS1HTR6HSD11B1ROCK2ROCK1 | |
| SCHEMBL21432180 | 0.82 | HDAC6 (0.39) | — | |
| SCHEMBL28361061 | 0.81 | FADS1 (0.37) | FADS1NPC1RAB9A | |
| SCHEMBL21432171 | 0.81 | FPR1 (0.32) | — | |
| SCHEMBL21432328 | 0.80 | CYP1A2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10729688-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190321360-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-10-24 | — | — | US | disclosed |
| WO-2019191166-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321360-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | FADS1 3359/4885HTR6 4588/4885HSD11B1 396/4885 |
| US-10729688-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | FADS1 3359/4885HTR6 4588/4885HSD11B1 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.